Showing results (1-10 of 79) with videos related to
Sort By:
Pageof 8
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|December 14, 2018
Regulatory and Evidence Requirements and the Changing Landscape in Regulation for Marketing AuthorisationFrancesco Pignatti, Elias PéanThe Journal of Ambulatory Care Management|April 9, 2004
Overview of the European regulatory approval systemFrancesco Pignatti, Hilde Boone, Isabelle MoulonMedical Decision Making : an International Journal of the Society for Medical Decision Making|September 10, 2019
From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk TradeoffsTommi Tervonen, Francesco Pignatti, Douwe PostmusMolecular Oncology|December 8, 2014
Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authoritiesFrancesco Pignatti, Bertil Jonsson, Gideon Blumenthal, et al.Chinese Clinical Oncology|April 6, 2015
The changing world of cancer drug development: the regulatory bodies' perspectiveIordanis Gravanis, Camille Vleminckx, Bertil Jonsson, et al.Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|May 21, 2021
Ethical Aspects of Regulating Oncology ProductsLorenzo Guizzaro, Spyridon Drosos, Ulrik Kihlbom, et al.Statistics in Medicine|September 27, 2022
A simulated maximum likelihood procedure for analyzing imprecise trade-off thresholds between the benefits and harms of medicinesDouwe Postmus, Francesco Pignatti, Hans L Hillege, et al.Clinical Pharmacology and Therapeutics|August 4, 2023
Queries Raised During Oncology Business Pipeline Meetings at the European Medicines Agency: A 5-Year Retrospective AnalysisC Mircea S Tesileanu, Francesco Pignatti, Enrico Tognana, et al.Nature Reviews. Drug Discovery|September 13, 2008
Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemmaHans-Georg Eichler, Francesco Pignatti, Bruno Flamion, et al.Clinical Pharmacology and Therapeutics|April 1, 2019
Quantifying Preferences in Drug Benefit-Risk DecisionsTommi Tervonen, Aris Angelis, Kimberley Hockley, et al.Pageof 8